Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium...
Aimmune begins enrolling egg allergy patients in Phase II study
Aimmune Therapeutics has recruited the first patient in a Phase II clinical trial evaluating investigational biological drug AR201 for the treatment of egg allergy.
Aurinia still has potential Phase III lupus nephritis mortality risk
Lupus nephritis is an inflammation of the kidney caused by systemic lupus erythematosus.
Provention Bio doses first patients in PREVAIL trial of PRV-3279
Provention Bio has dosed the first patients in its Phase Ib/IIa PREVAIL clinical trial of humanised diabody PRV-3279.
Janssen to trial mosaic-based HIV-1 preventive vaccine
Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.
Dolutegravir plus lamivudine yields positive data in HIV study
ViiV Healthcare has reported that the Phase III TANGO clinical trial of dolutegravir plus lamivudine met the primary endpoint of controlling HIV-1 infection in virally suppressed patients.
ViiV launches trial to implement monthly injectable HIV therapy
ViiV Healthcare has launched the new CUSTOMIZE trial to identify and assess approaches for implementing its once-monthly injectable HIV treatment, cabotegravir (ViiV Healthcare) plus rilpivirine (Janssen), into clinical practice.
J&J’s Phase IIb HIV prevention trial reaches full enrolment
Johnson & Johnson (J&J) has completed enrolment procedures for the Phase IIb Imbokodo clinical trial of an investigational, mosaic-based vaccine regimen to prevent HIV-1 infection.
NIH’s LATITUDE trial to study long-acting HIV regimen
A new National Institutes of Health (NIH)-funded clinical trial has been started to assess a long-acting antiretroviral therapy (ART) for the treatment of people living with HIV.
ViiV Healthcare unveils Phase III trial results of monthly shots to combat HIV
The results investigated the efficacy and safety of cabotegravir/rilpivirine, the company’s once-monthly injection for treating HIV.